

To: [REDACTED] [REDACTED] [REDACTED]@rivm.nl]
Cc: [REDACTED] [REDACTED] [REDACTED]@rivm.nl]
From: [REDACTED] [REDACTED]
Sent: Thur 11/26/2020 3:28:20 PM
Subject: Vaccine efficacy with human challenge data
Received: Thur 11/26/2020 3:30:04 PM
[Outline MS ModeOfAction Vaccines 26Nov2020 \[REDACTED\].docx](#)
[PDF Outline MS ModeOfAction Vaccines 26Nov2020 \[REDACTED\].pdf](#)

Hi [REDACTED],

As discussed last Tuesday, I am sending you a draft that includes preliminary results and a (tentative) manuscript outline.

Although figures and texts should be updated, through this rough document, I would like to have your comments especially on the below points:

1. Do the proposed method and formulation (model (iii) in the manuscript and its interpretation) look convincing?
2. I used Halloran and Longini's frailty model (model (iv) in the manuscript) as an additional discussion point, to compare it with the results of our proposed model. Does this make any confusion for potential readers? (Should this result be moved to Appendix?)

I'm planning to write this paper as a short report (less than 2500 words in the main text), but if you have any suggestions to include other results, it would be also very appreciated.

Best,

[REDACTED]

--

[REDACTED]

Unit of Infectious Disease Modeling, Center for Infectious Disease Control,
The National Institute for Public Health and the Environment (RIVM)
Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands

Center for Marine Environmental Studies (CMES),
Ehime University
Bunkyo-cho 3, Matsuyama, 7908577 Ehime, Japan